Safety and Clinical Performance of the Next-Generation SAFESYNC Transcatheter Heart Valve in Patients With Severe Aortic Stenosis (SAFESYNC NG)
Evaluation of the Safety and Clinical Performance of the Next-Generation SAFESYNC Balloon-Expandable Transcatheter Heart Valve in Patients With Severe Aortic Stenosis: A Prospective, Multicenter, Single-Arm Pivotal Study
This pivotal, prospective, multicenter (Brazil, Chile and Argentina), single-arm study will evaluate the safety and clinical performance of the Inovare® Safesync Next-Generation bioprosthetic heart valve, implanted by transfemoral transcatheter aortic valve implantation (TAVI) with the B-Delivery System, in patients aged 70 years or older with severe aortic stenosis and an indication for TAVI, regardless of surgical risk. The study will enroll 210 participants.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
Intervence / Léčba
Intervence / Léčba
Typ studie
Typ studie
Zápis (Odhadovaný)
Zápis
Fáze
Fáze
- Nelze použít
Kontakty a umístění
Studijní kontakt
Studijní kontakt
- Jméno: Clinical Research Department - Braile Biomédica
- Telefonní číslo: +5517 21367000
- E-mail: pesquisa@braile.com.br
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
Severe aortic valve stenosis diagnosed according to criteria established in current guidelines; Age ≥70 years, regardless of surgical risk; Indication for transcatheter aortic valve implantation (TAVI); Willing to participate and to sign the written informed consent form.
Exclusion Criteria:
Any condition considered a contraindication to implantation of a bioprosthetic heart valve (e.g., patient with an indication for a mechanical heart valve);
Known hypersensitivity or contraindication to any of the following that cannot be adequately managed with premedication:
- Aspirin, clopidogrel, or heparin (heparin-induced thrombocytopenia [HIT] or heparin-induced thrombocytopenia with thrombosis [HITTS]);
- Nitinol (titanium or nickel);
- Contrast media; Blood dyscrasias: leukopenia (white blood cell count <1,000/mm³), thrombocytopenia (platelet count <100,000 cells/mm³), history of coagulopathy, or hypercoagulable states; Active infection, including endocarditis; Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or need for mechanical hemodynamic support; Recent stroke or transient ischemic attack (within 6 months); History of gastrointestinal bleeding or other bleeding that precludes anticoagulant or antiplatelet therapy; Estimated life expectancy of less than 5 years; Other medical, social, or psychological conditions that, in the investigator's opinion, prevent the patient from providing consent or adequately complying with the protocol; Pre-existing prosthetic heart valve in the aortic position (biological or mechanical); Concomitant severe mitral or tricuspid valve disease; Hypertrophic obstructive cardiomyopathy; Percutaneous coronary intervention performed within 72 hours prior to the study procedure; Femoral artery diameter <5.5 mm (for Safesync 20 to 24 mm), <6.0 mm (for Safesync 26 and 28 mm), or <6.5 mm (for Safesync 30 mm); High risk of annular rupture or significant residual paravalvular leak due to severe calcification of the aortic valve or left ventricular outflow tract; High risk of coronary obstruction (coronary ostial height <10 mm with narrow sinuses of Valsalva [SOV], defined as a mean SOV diameter <3 mm larger than the bioprosthesis size), as determined by computed tomography angiography; Left ventricular dysfunction with left ventricular ejection fraction (LVEF) ≤30%; Severe chronic kidney disease, defined as glomerular filtration rate <30 mL/min/1.73 m².
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: INOVARE® SAFESYNC Next-Generation TAVI
|
Participants will undergo TAVI via transfemoral access using the INOVARE® SAFESYNC Next-Generation Bioprosthetic Heart Valve and the B-Delivery System. |
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Device Success According to VARC-3 Criteria
Časové okno: 30 days after the procedure
|
Technical success; Absence of mortality; Absence of surgery or intervention related to the device or to major vascular, access-related, or cardiac structural complications; Intended valve performance, defined as mean transvalvular gradient <20 mmHg, peak velocity <3 m/s, Doppler velocity index ≥0.25, and less than moderate aortic regurgitation. |
30 days after the procedure
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Percentage of Participants Achieving Technical Success According to VARC-3 Criteria
Časové okno: During the procedure
|
Defined as freedom from mortality; successful vascular access, delivery of the device, and retrieval of the delivery system; correct positioning of a single prosthetic heart valve in the intended anatomical location; and freedom from surgery or intervention related to the device or to a major vascular, access-related, or cardiac structural complication. Results will be reported as the number and percentage of participants achieving technical success. |
During the procedure
|
|
Incidence and Severity of Paravalvular Leak
Časové okno: 30 days, 6 months, 12 months, and annually through 5 years
|
Paravalvular leak will be assessed by transthoracic echocardiography and classified according to severity. The number and percentage of participants with paravalvular leak in each severity category will be reported. |
30 days, 6 months, 12 months, and annually through 5 years
|
|
Mean Transvalvular Aortic Pressure Gradient Assessed
Časové okno: 30 days, 6 months, 12 months, and annually through 5 years
|
Mean transvalvular aortic pressure gradient will be assessed by transthoracic echocardiography and reported in mmHg. |
30 days, 6 months, 12 months, and annually through 5 years
|
|
Distribution of Participants by New York Heart Association Functional Class
Časové okno: 30 days, 6 months, 12 months, and annually through 5 years
|
Functional status will be assessed using the New York Heart Association (NYHA) Functional Classification. The classification ranges from Class I to Class IV, where Class I represents no limitation of physical activity and Class IV represents inability to perform physical activity without symptoms and/or symptoms at rest. Higher NYHA classes indicate worse functional status. Results will be reported as the number and percentage of participants in each NYHA functional class. |
30 days, 6 months, 12 months, and annually through 5 years
|
|
Incidence of New Permanent Pacemaker Implantation
Časové okno: 30 days, 6 months, 12 months, and annually through 5 years
|
New permanent pacemaker implantation following the index transcatheter aortic valve implantation procedure will be assessed. Results will be reported as the number and percentage of participants who undergo new permanent pacemaker implantation. |
30 days, 6 months, 12 months, and annually through 5 years
|
|
Incidence of All-Cause Mortality
Časové okno: 30 days, 6 months, 12 months, and annually through 5 years
|
All-cause mortality will be assessed throughout follow-up. Results will be reported as the number and percentage of participants who die from any cause. |
30 days, 6 months, 12 months, and annually through 5 years
|
|
Incidence of Stroke
Časové okno: 30 days, 6 months, 12 months, and annually through 5 years
|
Stroke events will be assessed based on clinical neurological evaluation and classified according to Valve Academic Research Consortium 3 (VARC-3) definitions. Results will be reported as the number and percentage of participants experiencing stroke. |
30 days, 6 months, 12 months, and annually through 5 years
|
|
Incidence of Bioprosthetic Valve-Related Reintervention
Časové okno: 30 days, 6 months, 12 months, and annually through 5 years
|
Bioprosthetic valve-related reintervention will be defined as any surgical or transcatheter intervention performed to treat dysfunction or failure of the implanted study valve. Results will be reported as the number and percentage of participants undergoing valve-related reintervention. |
30 days, 6 months, 12 months, and annually through 5 years
|
|
Incidence of Bioprosthetic Valve Dysfunction According to VARC-3 Definitions
Časové okno: 30 days, 6 months, 12 months, and annually through 5 years
|
Bioprosthetic valve dysfunction will be assessed according to Valve Academic Research Consortium 3 (VARC-3) definitions. Bioprosthetic valve dysfunction includes structural valve deterioration, non-structural valve dysfunction, valve thrombosis, and endocarditis. Results will be reported as the number and percentage of participants meeting the criteria for bioprosthetic valve dysfunction and according to the corresponding category. |
30 days, 6 months, 12 months, and annually through 5 years
|
|
Incidence of Bioprosthetic Valve Failure According to VARC-3 Definitions
Časové okno: 30 days, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months after the index procedure
|
Bioprosthetic valve failure will be assessed according to Valve Academic Research Consortium 3 (VARC-3) definitions. Results will be reported as the number and percentage of participants meeting the criteria for bioprosthetic valve failure. |
30 days, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months after the index procedure
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Odhadovaný)
Začátek studia
Primární dokončení (Odhadovaný)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
Další identifikační čísla studie
- SAFESYNC NG
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .